Related references
Note: Only part of the references are listed.Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor
Alexey E. Granovsky et al.
CELL RESEARCH (2008)
Wide variation in surgical outcomes for acromegaly in the UK
P. R. Bates et al.
CLINICAL ENDOCRINOLOGY (2008)
Clinicopathological features of growth hormone-producing pituitary adenomas: Difference among various types defined by cytokeratin distribution pattern including a transitional form
Abdulkader Obari et al.
ENDOCRINE PATHOLOGY (2008)
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
I. M. Holdaway et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal
Cristina L. Ronchi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
Giselle F. Taboada et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Cabergoline and the risk of valvular lesions in endocrine disease
Patrizio Lancellotti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Lipodystrophy in patients with acromegaly receiving pegvisomant
Vivien S. Bonert et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Correlation of in Vitro and in Vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy
Diego Ferone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Extensive clinical experience: Changing patterns in diagnosis and therapy of acromegaly over two decades
Lisa Nachtigall et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma
Marleen Kars et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma
Marco Losa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Low levels of Raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment
Stine Lyngvi Fougner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial
Sven M. Carlsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas
Ursula Ploeckinger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Mortality in acromegaly: A meta analysis
O. M. Dekkers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Somatostatin agonists for treatment of acromegaly
Anat Ben-Shlomo et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization
Michael Grant et al.
MOLECULAR ENDOCRINOLOGY (2008)
The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma
Stine L. Fougner et al.
CLINICAL ENDOCRINOLOGY (2008)
Management of acromegaly: Is there a role for primary medical therapy?
Zachary M. Bush et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2008)
A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly
Magdalene Andries et al.
CLINICAL ENDOCRINOLOGY (2008)
Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: Good correlation with preoperative response to octreotide
Mao Takei et al.
ENDOCRINE PATHOLOGY (2007)
Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas
Zhi Rong Qian et al.
MODERN PATHOLOGY (2007)
Long-term efficacy and safety of combined treatment of somatostatin analogs and Pegvisomant in acromegaly
Sebastian J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
AcroBel - the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects
Marie Bex et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Concomitant, specific determination of growth hormone and pegvisomant in human serum
H. Orskov et al.
GROWTH HORMONE & IGF RESEARCH (2007)
Gsα overexpression and loss of Gsα imprinting in human somatotroph adenomas:: Association with tumor size and response to pharmacologic treatment
Christophe Picard et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors:: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission
Pamela U. Freda et al.
PITUITARY (2007)
Gamma knife stereotactic radiosurgery for acromegaly
Einar Osland Vik-Mo et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa
Jean Christophe Maiza et al.
CLINICAL ENDOCRINOLOGY (2007)
A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors
Sylvia L. Asa et al.
CANCER RESEARCH (2007)
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
Moises Mercado et al.
CLINICAL ENDOCRINOLOGY (2007)
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient
Eugenia Resmini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Pegvisomant interference in GH assays results in underestimation of GH levels
A. N. Paisley et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Dopamine agonists and the risk of cardiac-valve regurgitation
Rene Schade et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas
Giselle F. Taboada et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
I. Schreiber et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients
T. Ueland et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: Preferential expression of somatostatin receptor subtype 3
A. P. M. Casarini et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2006)
Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2
E. Ferrante et al.
ENDOCRINE-RELATED CANCER (2006)
Presurgical treatment with somatostatin analogs in patients with acromegaly:: effects on the remission and complication rates
M Losa et al.
JOURNAL OF NEUROSURGERY (2006)
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: A prospective study in 99 patients
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Recent developments in the therapy of acromegaly
AN Paisley et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial
A Colao et al.
CLINICAL ENDOCRINOLOGY (2006)
Nanomedicines in the treatment of acromegaly: focus on pegvisomant
Ferdinand Roelfsema et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2006)
Consensus statement: medical management of acromegaly
S Melmed et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly
S Bhayana et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro
C Zatelli et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2005)
Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist
JOL Jorgensen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Cytokeratin CK 7 and CK 20 expression in pituitary adenomas
SW Coons et al.
ENDOCRINE PATHOLOGY (2005)
Outcome of gamma knife radiosurgery in 82 patients with acromegaly:: Correlation with initial hypersecretion
F Castinetti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
A nationwide survey of mortality in acromegaly
R Kauppinen-Mäkelin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
J Feenstra et al.
LANCET (2005)
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly
JS Bevan
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'
P Nomikos et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: The relationship with endogenous SRIF activity and response to octreotide
CY Park et al.
ENDOCRINE JOURNAL (2004)
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly
J Ayuk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Pharmacokinetics of a new autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers
RM Antonijoan et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
J van der Hoek et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Factors influencing mortality in acromegaly
IM Holdaway et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Systemic complications of acromegaly: Epidemiology, pathogenesis, and management
A Colao et al.
ENDOCRINE REVIEWS (2004)
Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR
O Alexopoulou et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status
R Cozzi et al.
CLINICAL ENDOCRINOLOGY (2004)
Determinants of survival in treated acromegaly in a single center: Predictive value of serial insulin-like growth factor I measurements
NR Biermasz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes
G Tulipano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2
K Lorenz et al.
NATURE (2003)
Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant
WM Drake et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
Optimizing control of acromegaly: Integrating a growth hormone receptor antagonist into the treatment algorithm
DR Clemmons et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Transsphenoidal surgery for acromegaly in Wales: Results based on stringent criteria of remission
P De et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas
H Nishioka et al.
CLINICAL ENDOCRINOLOGY (2003)
Topoisomerase IIα expression in pituitary adenomas and carcinomas:: Relationship to tumor behavior
S Vidal et al.
MODERN PATHOLOGY (2002)
Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size
JS Bevan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
C Bruns et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly
T Ueland et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2002)
Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues
ST Wahid et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas:: analysis of gene sequence and mRNA expression
S Corbetta et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2001)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
M Rocheville et al.
SCIENCE (2000)
Octreotide effect on growth hormone and somatostatin subtype 2 receptor mRNAs of the human pituitary somatotroph adenomas
L Stefaneanu et al.
ENDOCRINE PATHOLOGY (2000)
Share Paper
